X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15) 15
melanoma (13) 13
humans (12) 12
oncology (11) 11
female (10) 10
hematology, oncology and palliative medicine (10) 10
male (10) 10
melanoma - drug therapy (9) 9
metastasis (9) 9
middle aged (9) 9
aged (8) 8
clinical trials (8) 8
ipilimumab (8) 8
studies (8) 8
survival (8) 8
adult (7) 7
care and treatment (7) 7
aged, 80 and over (6) 6
double-blind method (6) 6
analysis (5) 5
immunotherapy (5) 5
medical colleges (5) 5
mutation (5) 5
skin neoplasms - drug therapy (5) 5
skin neoplasms - pathology (5) 5
disease progression (4) 4
disease-free survival (4) 4
drug dosages (4) 4
follow-up studies (4) 4
nivolumab (4) 4
prognosis (4) 4
surgery (4) 4
treatment outcome (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer (3) 3
cutaneous melanoma (3) 3
imidazoles - administration & dosage (3) 3
lymphatic system (3) 3
medical prognosis (3) 3
melanoma - genetics (3) 3
melanoma - mortality (3) 3
melanoma - pathology (3) 3
melanoma - secondary (3) 3
metastases (3) 3
metastatic melanoma (3) 3
neoplasm staging (3) 3
oximes - administration & dosage (3) 3
patients (3) 3
pembrolizumab (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
pyridones - administration & dosage (3) 3
pyrimidinones - administration & dosage (3) 3
quality of life (3) 3
risk factors (3) 3
scores (3) 3
skin cancer (3) 3
vemurafenib (3) 3
young adult (3) 3
abridged index medicus (2) 2
adjuvants, immunologic (2) 2
adolescent (2) 2
antibodies, monoclonal (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, monoclonal - therapeutic use (2) 2
antigens (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
cancer therapies (2) 2
carcinoma, basal cell - drug therapy (2) 2
carcinoma, basal cell - pathology (2) 2
case-control studies (2) 2
chemotherapy (2) 2
colitis (2) 2
dermatology (2) 2
diarrhea (2) 2
dose-response relationship, drug (2) 2
drug administration schedule (2) 2
drug therapy (2) 2
epidemiology (2) 2
european-organization (2) 2
hematology, oncology, and palliative medicine (2) 2
imidazoles - therapeutic use (2) 2
immune checkpoint (2) 2
intention to treat analysis (2) 2
internal medicine (2) 2
intravenous administration (2) 2
kinases (2) 2
life sciences (2) 2
medical research (2) 2
medicine, general & internal (2) 2
mek inhibition (2) 2
melanoma - surgery (2) 2
metaanalysis (2) 2
motivation (2) 2
node-positive melanoma (2) 2
oximes - therapeutic use (2) 2
patient outcomes (2) 2
patient safety (2) 2
pd-1 protein (2) 2
prospective studies (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article